6 results on '"Sokolov, Vladimir"'
Search Results
2. Bis-γ-carbolines as new potential multitarget agents for Alzheimer's disease.
- Author
-
Makhaeva, Galina F., Shevtsova, Elena F., Aksinenko, Alexey Y., Kovaleva, Nadezhda V., Boltneva, Natalia P., Lushchekina, Sofya V., Rudakova, Еlena V., Pushkareva, Elena A., Serkova, Tatyana P., Dubova, Lyudmila G., Shevtsov, Pavel N., Sokolov, Vladimir B., Radchenko, Eugene V., Palyulin, Vladimir A., Bachurin, Sergey O., and Richardson, Rudy J.
- Subjects
ALZHEIMER'S disease ,INTRACELLULAR calcium ,BLOOD-brain barrier ,INTESTINAL absorption ,MOLECULAR docking ,THERAPEUTICS - Abstract
A new series of homobivalent Dimebon analogs, bis-γ-carbolines with alkylene, phenylenedialkylene, and triazole-containing spacers, was synthesized. Doubling the γ-carboline pharmacophore increased inhibitory potency against acetylcholinesterase (AChE) compared with Dimebon, while keeping Dimebon's anti-butyrylcholinesterase activity; therefore, leading to inversion of selectivity. Molecular docking revealed the reasons for the increased anti-AChE activity and ability to block AChE-induced aggregation of β-amyloid for bis-γ-carbolines, which became double-site inhibitors of AChE. Conjugates with ditriazole-containing spacers were the most active antioxidants in both the ABTS-test and prevention of lipid peroxidation in brain homogenates without inhibiting the mitochondrial permeability transition (MPT). Conjugates with alkylene (4a–d), phenylenedialkylene (4e), and monotriazole (8) spacers were less active as antioxidants but prevented induction of the MPT and increased the calcium retention capacity of mitochondria. Lead compound 4e showed neuroprotective potential in a cellular calcium overload model of neurodegeneration. Computational studies showed that all the bis-γ-carbolines were expected to have high values for intestinal absorption and very good blood-brain barrier permeability along with good drug-likeness. Overall, the results showed that new homobivalent Dimebon analogs exhibit an expanded spectrum of biological activity and improved pharmacological properties, making them promising candidates for further research and optimization as multitarget agents for Alzheimer's disease treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Focused design of polypharmacophoric neuroprotective compounds: Conjugates of γ-carbolines with carbazole derivatives and tetrahydrocarbazole.
- Author
-
Makhaeva, Galina F., Sokolov, Vladimir B., Shevtsova, Elena F., Kovaleva, Nadezhda V., Lushchekina, Sofya V., Boltneva, Natalia P., Rudakova, Elena V., Aksinenko, Alexey Yu., Shevtsov, Pavel N., Neganova, Margarita E., Dubova, Ludmila G., and Bachurin, Sergey O.
- Subjects
- *
ALZHEIMER'S disease , *CARBAZOLE , *CARBOLINES , *MICROTUBULES , *NEURODEGENERATION - Abstract
Alzheimer's disease has a complex multifactorial nature; therefore, a promising approach for the development of efficient therapeutic agents is the concept of multitarget drugs, which affect several biological targets involved in the pathogenesis of the disease. We developed a synthetic algorithm for conjugating several pharmacophoric ligands acting on the key stages of pathogenesis of several neurodegenerative diseases and synthesized hybrid structures combining the γ-carboline fragment of Dimebon with carbazole and tetrahydrocarbazole moieties. Using the complex primary screening system the structures have been revealed that combine the high inhibitory activity and selectivity towards butyrylcholinesterase with the radical-scavenging activity and the ability to potentiate tubulin polymerization to microtubules with a normal structure and/or prevent mitochondrial permeability transition. The lead compound was identified for future optimization and development of new multi-target drugs against neurodegenerative diseases combining the cognitive-stimulating and neuroprotective potentials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Chronic Administration of Dimebon Ameliorates Pathology in TauP301S Transgenic Mice.
- Author
-
Peters, Owen M., Connor-Robson, Natalie, Sokolov, Vladimir B., Aksinenko, Alexey Yu., Kukharsky, Michail S., Bachurin, Sergey O., Ninkina, Natalia, and Buchman, Vladimir L.
- Subjects
ALZHEIMER'S patients ,PATHOLOGY ,TRANSGENIC mice ,NEURODEGENERATION ,CARBOLINES - Abstract
Dimebon belongs to a fast-growing group of 'old' drugs that were suggested to be effective for therapy of pathological conditions different from their original targets. Following initial reports of successful Phase II clinical trials for mild-to-moderate Alzheimer's and Huntington's diseases, effects of Dimebon on various neurodegenerative conditions were investigated both in follow-up clinical trials and in various model systems. Although results of Phase III clinical trials carried out so far were disappointing, there is growing body of evidence that this drug can affect neuronal physiology in a way that would be beneficial at particular stages of development of certain types of neurodegeneration. To reveal what molecular and cellular pathological processes might be affected by Dimebon, we tested the ability of this drug to ameliorate pathology in model systems recapitulating particular pathogenic mechanisms involved in the development and progression of neurodegenerative diseases. Here we assessed the ability of Dimebon to modify several prominent features of tauopathies using transgenic tau
P301S mice as a model. Chronic treatment with Dimebon was found to partially protect against the progressive decline in motor function and accumulation of tau-positive dystrophic neurons characteristic of tauP301S mice. Similar results were obtained with two further γ-carbolines structurally similar to Dimebon. Our data suggest that Dimebon and Dimebon-like compounds might be considered as drugs possessing disease-modifying activity for diseases with prominent tau pathology. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
5. Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice.
- Author
-
Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL, Peters, Owen M, Connor-Robson, Natalie, Sokolov, Vladimir B, Aksinenko, Alexey Yu, Kukharsky, Michail S, Bachurin, Sergey O, Ninkina, Natalia, and Buchman, Vladimir L
- Subjects
ALZHEIMER'S disease ,ANIMAL experimentation ,DRUG administration ,MICE ,NERVE tissue proteins ,NEURODEGENERATION ,RESEARCH funding ,NEUROPROTECTIVE agents ,INDOLE compounds - Abstract
Dimebon belongs to a fast-growing group of "old" drugs that were suggested to be effective for therapy of pathological conditions different from their original targets. Following initial reports of successful Phase II clinical trials for mild-to-moderate Alzheimer's and Huntington's diseases, effects of Dimebon on various neurodegenerative conditions were investigated both in follow-up clinical trials and in various model systems. Although results of Phase III clinical trials carried out so far were disappointing, there is growing body of evidence that this drug can affect neuronal physiology in a way that would be beneficial at particular stages of development of certain types of neurodegeneration. To reveal what molecular and cellular pathological processes might be affected by Dimebon, we tested the ability of this drug to ameliorate pathology in model systems recapitulating particular pathogenic mechanisms involved in the development and progression of neurodegenerative diseases. Here we assessed the ability of Dimebon to modify several prominent features of tauopathies using transgenic tauP301S mice as a model. Chronic treatment with Dimebon was found to partially protect against the progressive decline in motor function and accumulation of tau-positive dystrophic neurons characteristic of tauP301S mice. Similar results were obtained with two further γ-carbolines structurally similar to Dimebon. Our data suggest that Dimebon and Dimebon-like compounds might be considered as drugs possessing disease-modifying activity for diseases with prominent tau pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.
- Author
-
Makhaeva, Galina F., Lushchekina, Sofya V., Boltneva, Natalia P., Sokolov, Vladimir B., Grigoriev, Vladimir V., Serebryakova, Olga G., Vikhareva, Ekaterina A., Aksinenko, Alexey Yu., Barreto, George E., Aliev, Gjumrakch, and Bachurin, Sergey O.
- Subjects
ALZHEIMER'S disease ,NEUROPROTECTIVE agents ,METHYLENE blue ,CARBOLINES ,PHENOTHIAZINE - Abstract
Alzheimer disease is a multifactorial pathology and the development of new multitarget neuroprotective drugs is promising and attractive. We synthesized a group of original compounds, which combine in one molecule γ-carboline fragment of dimebon and phenothiazine core of methylene blue (MB) linked by 1-oxo- and 2-hydroxypropylene spacers. Inhibitory activity of the conjugates toward acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and structurally close to them carboxylesterase (CaE), as well their binding to NMDA-receptors were evaluated in vitro and in silico. These newly synthesized compounds showed significantly higher inhibitory activity toward BChE with IC
50 values in submicromolar and micromolar range and exhibited selective inhibitory action against BChE over AChE and CaE. Kinetic studies for the 9 most active compounds indicated that majority of them were mixed-type BChE inhibitors. The main specific protein-ligand interaction is π-π stacking of phenothiazine ring with indole group of Trp82. These compounds emerge as promising safe multitarget ligands for the further development of a therapeutic approach against aging-related neurodegenerative disorders such as Alzheimer and/or other pathological conditions. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.